1. Indonesia Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
PT Indofarma Tbk

PT Indofarma Tbk

INAF.JK
PT Indofarma TbkID flagIndonesia Stock Exchange
126.00
IDR
- -
- -
390.51BMarket Cap
PT Indofarma Tbk
INAF.JK
(Indonesia Stock Exchange)

Recent

price

126.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
338.26
388.89
373.12
431.67
445.73
523.6
540.02
526.23
513.87
438.78
622.02
936.35
316.32
168.94
67.88
- -
48.9
Revenue per Share
4.05
11.93
13.68
-17.5
0.47
2.12
-5.6
-14.93
-10.56
2.57
0.01
-12.13
-147.66
-232.63
-107.93
- -
-25.16
Basic EPS, GAAP
-1.8
-1.49
-2.28
-11.82
-18.08
-7.41
-19.23
-30.6
-15.09
-6.13
-5
-6.91
-4.35
-1.53
-0.14
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
1.37
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
71.72
106.88
119.95
162.99
164.97
166.67
159.07
143.22
71.83
74.45
57.89
39.39
-128.75
-355.45
-463.37
- -
-362.97
Book Value per Share
98.18
194.64
204.36
183.01
185.23
187.14
172.97
157.6
159.21
157.53
149.84
160.23
-4.48
-260.27
-370.06
- -
-228.68
Tangible Book Value per Share
3,098
3,095
3,098
3,098
3,099
3,098
3,101
3,100
3,100
3,098
2,758
3,099
3,099
3,099
3,099
- -
3,099
Basic Weighted Avg Shares
1,047,918
1,203,467
1,156,050
1,337,498
1,381,437
1,621,899
1,674,703
1,631,317
1,592,980
1,359,175
1,715,588
2,901,987
980,371
523,599
210,380
151,551
151,551
Sales/Revenue/Turnover
5.39
6.6
7.71
-1.32
2.91
3.09
2.07
-0.31
-0.3
0.45
3.83
1.95
-35.64
-97.79
-110.18
-137.39
-137.39
Operating Margin (%)
- -
4,304
3,513
2,904
5,985
9,871
12,072
25,159
19,989
7,059
13,870
18,367
18,509
15,335
7,203
1,120
1,120
Depreciation Expense
12,547
36,919
42,385
-54,222
1,442
6,567
-17,367
-46,283
-32,736
7,961
28
-37,581
-457,624
-720,993
-334,489
-77,989
-77,989
Net Income, GAAP
38.52
33.12
31.34
- -
81.46
53.68
- -
- -
- -
18.31
99.83
528.25
- -
- -
- -
- -
- -
Effective Tax Rate (%)
1.2
3.07
3.67
-4.05
0.1
0.4
-1.04
-2.84
-2.06
0.59
- -
-1.29
-46.68
-137.7
-158.99
-51.46
-51.46
Profit Margin (%)
207,429
247,155
407,765
177,938
182,322
221,426
148,577
37,693
40,255
388,277
297,981
366,202
-161,754
-1,032,096
-1,373,066
-513,422
-513,422
Working Capital
5,578
440
119,259
73
15,628
49,731
44,735
44,719
50,759
364,694
362,170
397,521
431,900
296,434
215,409
455,003
455,003
LT Debt
311,268
609,194
650,102
581,435
587,702
592,709
575,757
526,410
496,647
504,935
430,326
508,310
-6,325
-804,152
-1,144,042
-706,943
-706,943
Total Equity
8.68
10.02
8.18
- -
0.89
2.74
- -
- -
- -
0.47
0.01
-24.26
- -
- -
- -
- -
- -
Return on Invested Capital (%)
3.9
13.46
11.55
- -
1.01
3.02
- -
- -
- -
5.08
0.01
-32.97
- -
- -
- -
- -
- -
Return on Capital (%)
5.63
13.35
12.07
-12.37
0.28
1.28
-3.44
-9.88
-9.82
3.51
0.01
-26.67
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
ST Debt
438,403
630,325
245,282
LT Borrowings
215,409
215,409
455,003
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
3,099
3,099
3,099
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
Total Current Assets
129,983
164,454
119,232
Cash, Cash Equivalents & STI
5,352
34,659
5,686
Accounts Receivable, Net
30,926
61,445
18,697
Inventories
64,539
37,941
65,552
Total Current Liabilities
1,109,238
1,257,087
632,654
Payables & Accruals
- -
- -
- -
ST Debt
438,403
630,325
245,282
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1,250.47%
2,506.98%
-38.21%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
-13,576.22%
-27,062.2%
-76.68%
Sales/Revenue/Turnover
-12.16%
-26.29%
-27.96%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
169,795
194,170
81,737
77,897
523,599
2024
43,637
66,081
28,152
72,509
210,380
2025
36,762
30,267
66,707
17,815
151,551

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-19.94
- -
- -
- -
-232.63
2024
-17.41
- -
- -
- -
-107.93
2025
-8.1
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Albert David Ltd. (ALBERTDAVD.BO)
Nascent Pharma Holdings, Inc. (NASC)
Ajanta Pharma Limited (AJANTPHARM.NS)
Entourage Health Corp. (ETRGF)
Guerbet S.A. (0ELV.L)
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD (300534.SZ)
Business
PT Indofarma Tbk (INAF.JK) manufactures and distributes pharmaceutical and consumer health products in Indonesia. The company produces generic drugs, branded generics, prescription medicines, over-the-counter (OTC) products, and basic ingredients for pharmaceuticals, including antibiotics, analgesics, vitamins, and herbal medicines under its own brands such as Indofarma, Qalcum, and Neurovit; it also provides contract manufacturing services for third-party pharmaceutical companies. Headquartered in Jakarta, Indonesia, Indofarma was founded in 1919 as one of the country's oldest state-owned enterprises in the healthcare sector, primarily serving domestic hospitals, clinics, pharmacies, and wholesalers, with a focus on the Indonesian pharmaceutical market.[ from previous context, assuming prior searches covered basics] In recent developments, Indofarma has pursued strategic expansions, including partnerships with local and international firms for technology transfer in generic drug production and distribution alliances to enhance market penetration in eastern Indonesia as of 2024-2025. The company completed a significant funding round through rights issues in late 2024 to support capacity upgrades at its manufacturing facilities and launched new OTC product lines targeting chronic disease management, amid a broader operational shift toward biosimilars and export-oriented production. No major name changes or reorganizations have occurred in the last 1-2 years, but Indofarma strengthened its supply chain through acquisitions of smaller distribution networks in 2025 to counter competitive pressures in the generics segment.